Paper Details

  1. Home
  2. Paper Details

High Prevalence of Genital Mycotic Infections with Sodium-glucose Co-transporter 2 Inhibitors among Indian Patients with Type 2 Diabetes.

Author: AggarwalAjay, KapoorDheeraj, KhannaRajeev, WadhwaRoopak

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This document discusses the increased risk of genital mycotic infections in patients with type 2 diabetes (T2D) taking sodium-glucose co-transporter 2 inhibitors (SGLT2i). The document points out that the data on the incidence of these infections in India is unclear.
Paper Details　
Original Abstract of the Article :
Genital mycotic infections are common among patients with poorly controlled diabetes. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) induced pharmacological glycosuria increases the risk of these infections (2-3 fold) among patients with type 2 diabetes (T2D). The data about incidence of these ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446664/

データ提供：米国国立医学図書館（NLM）

Sodium-glucose Co-transporter 2 Inhibitors and Genital Mycotic Infections: Navigating the Sands of Diabetes Treatment

Managing diabetes can be a challenging journey, requiring careful attention to medication adherence and potential side effects. This research focuses on the potential association between sodium-glucose co-transporter 2 inhibitors (SGLT2i) and genital mycotic infections (GMIs). The authors investigated the prevalence of GMIs among Indian patients with type 2 diabetes (T2D) who were using SGLT2i.

The Impact of SGLT2i on Genital Mycotic Infections

The study found a high prevalence of GMIs among Indian patients with T2D who were using SGLT2i. The authors suggest that the pharmacological glycosuria induced by SGLT2i may increase the risk of GMIs in this population.

Navigating the Risks and Benefits of SGLT2i

This research highlights the importance of considering the potential risks and benefits of SGLT2i in the management of T2D. Clinicians should be aware of the increased risk of GMIs in patients using SGLT2i and monitor their patients closely for any signs of infection.

Dr.Camel's Conclusion

This study reminds us that the desert of diabetes management is complex and requires a careful approach. Understanding the potential side effects of medications, such as SGLT2i, is crucial for ensuring the safety and well-being of patients with T2D.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-10-06
Further Info :

Pubmed ID

31016146

DOI: Digital Object Identifier

PMC6446664

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.